Advertisement

Topics

AZ books 3 percent sales drop for Q3

17:25 EST 9 Nov 2017 | PharmaTimes

AstraZeneca has booked another sales decline for the third quarter but says the impact of generic competition is starting to wane.

Original Article: AZ books 3 percent sales drop for Q3

NEXT ARTICLE

More From BioPortfolio on "AZ books 3 percent sales drop for Q3"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...